High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients

Mehta, Minesh; Slaughter, Crystal; Xanthakos, Stavra A.; Kohli, Rohit

doi:10.1016/j.dld.2014.03.014

Cited by 6 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced anti-HBs seroconversion rates were also found in adults with diabetes and renal disease compared to healthy adults 14 , 15 . Although one study found a high prevalence of HBV vaccine unresponsiveness in ~70% of pediatric patients with NAFLD 16 , another reported no difference in vaccine response rates in children with NAFLD compared to healthy controls 17 .…”

Section: Introductionmentioning

confidence: 99%

Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

et al. 2021

View full text Add to dashboard Cite

Obesity and cirrhosis are associated with poor hepatitis B virus (HBV) vaccine responses, but vaccine efficacy has not been assessed in nonalcoholic fatty liver disease (NAFLD). Sixty-eight HBV-naïve adults with NAFLD were enrolled through the Canadian HBV network and completed three-dose HBV or HBV/HAV vaccine (Engerix-B®, or Twinrix®, GlaxoSmithKline). Anti-HBs titers were measured at 1–3 months post third dose. In 31/68 subjects enrolled at the coordinating-site, T-cell proliferation and follicular T-helper cells (pTFH) were assessed using PBMC. Immune response was also studied in NAFLD mice. NAFLD patients were stratified as low-risk-obesity, BMI < 35 (N = 40) vs. medium-high-risk obesity, BMI > 35 (N = 28). Anti-HBs titers were lower in medium/high-risk obesity, 385 IU/L ± 79 vs. low-risk obesity class, 642 IU/L ± 68.2, p = 0.02. High-risk obesity cases, N = 14 showed lower vaccine-specific-CD3+ CD4+ T-cell response compared to low-risk obesity patients, N = 17, p = 0.02. Low vaccine responders showed dysfunctional pTFH. NAFLD mice showed lower anti-HBs levels and T-cell response vs. controls. In conclusion, we report here that obese individuals with NAFLD exhibit decreased HBV vaccine-specific immune responses.

show abstract

Section: Introductionmentioning

confidence: 99%

Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The liver, the largest visceral organ in the body, has been intimately associated with various diseases including chronic metabolic syndrome, inflammation, and cancer . Under pathological conditions, the activation of immune cells and inflammatory pathways lead to liver complications, including damage to hepatic metabolic homeostasis and a cluster of interrelated metabolic risk factors such as raised fasting glucose, central obesity, dyslipoproteinaemia, and hypertension . In addition, the damage of hepatic metabolic homeostasis and inflammatory disease has gained increasing attention for its relationship with end‐stage liver disease: primary liver cancer and hepatocellular carcinoma (HCC) …”

Section: Introductionmentioning

confidence: 99%

“…[6][7][8][9] Under pathological conditions, the activation of immune cells and inflammatory pathways lead to liver complications, including damage to hepatic metabolic homeostasis and a cluster of interrelated metabolic risk factors such as raised fasting glucose, central obesity, dyslipoproteinaemia, and hypertension. [10][11][12][13] In addition, the damage of hepatic metabolic homeostasis and inflammatory disease has gained increasing attention for its relationship with end-stage liver disease: primary liver cancer and hepatocellular carcinoma (HCC). [14][15][16] Several transcription factors are concurrently critical mediators in the regulation of biological processes, especially under illness stress.…”

mentioning

confidence: 99%

PCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer

Yao

Shao

Zheng

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

The P300/CBP‐associating factor (PCAF), a histone acetyltransferase, is involved in metabolic and pathogenic diseases, particularly of the liver. The effects of PCAF on fine‐tuning liver diseases are extremely complex and vary according to different pathological conditions. This enzyme has dichotomous functions, depending on differently modified sites, which regulate the activities of various enzymes, metabolic functions, and gene expression. Here, we summarize the most recent findings on the functions and targets of PCAF in various metabolic and immunological processes in the liver and review these new discoveries and models of PCAF biology in three areas: hepatic metabolic syndrome, inflammatory disease, and cancer. Finally, we discuss the potential implications of these findings for therapeutic interventions in liver diseases.

show abstract

Good response to the primary course and booster dose of hepatitis B vaccine in children with non-alcoholic fatty liver disease

Seniuta

Miśkiewicz

Szenborn

2017

Digestive and Liver Disease

View full text Add to dashboard Cite

High prevalence of hepatitis B non-immunity in paediatric non-alcoholic fatty liver disease patients

Cited by 6 publications

References 4 publications

Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)

PCAF fine‐tunes hepatic metabolic syndrome, inflammatory disease, and cancer

Good response to the primary course and booster dose of hepatitis B vaccine in children with non-alcoholic fatty liver disease

Contact Info

Product

Resources

About